This article is from the source 'bbc' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at http://www.bbc.co.uk/news/business-27291162

The article has changed 14 times. There is an RSS feed of changes available.

Version 4 Version 5
Astra ex-boss fears Pfizer will be a 'praying mantis' Astra's former boss fears Pfizer will be 'praying mantis'
(35 minutes later)
The former chief executive of AstraZeneca has attacked the attempted takeover of the UK pharmaceuticals firm by its US rival Pfizer.The former chief executive of AstraZeneca has attacked the attempted takeover of the UK pharmaceuticals firm by its US rival Pfizer.
Sir David Barnes was chief executive of AstraZeneca until 2000 and deputy chairman until 2002.Sir David Barnes was chief executive of AstraZeneca until 2000 and deputy chairman until 2002.
He told the BBC's business editor Kamal Ahmed he feared Pfizer would act like a "praying mantis" and "suck the lifeblood" out of AstraZeneca.He told the BBC's business editor Kamal Ahmed he feared Pfizer would act like a "praying mantis" and "suck the lifeblood" out of AstraZeneca.
Pfizer offered £63bn for the UK pharmaceutical giant on Friday.Pfizer offered £63bn for the UK pharmaceutical giant on Friday.
The offer - the second Pfizer has made for AstraZeneca - was immediately rejected by the board of the UK pharmaceutical firm, which said Pfizer continued to "significantly undervalue" the company.The offer - the second Pfizer has made for AstraZeneca - was immediately rejected by the board of the UK pharmaceutical firm, which said Pfizer continued to "significantly undervalue" the company.
It comes as MPs are to probe the planned takeover of AstraZeneca by Pfizer.It comes as MPs are to probe the planned takeover of AstraZeneca by Pfizer.
Two parliamentary select committees - the Business Select Committee and the Science and Technology committee - have said they intend summon the bosses of both companies to answer questions at the hearing. Two parliamentary select committees - the Business Select Committee and the Science and Technology committee - have said they intend to summon the bosses of both companies to answer questions at the hearing.
The Business committee hearing is likely to happen "quite soon" and possibly within the next week, the BBC has learned. The Business Committee hearing is likely to happen "quite soon" and possibly within the next week, the BBC has learned.
The science and technology committee is also planning a hearing over the deal and wants to hear from bosses. 'Serious concern'
Science and technology committee chair Andrew Miller said that there was "serious concern - to say the least" about the proposed takeover.Science and technology committee chair Andrew Miller said that there was "serious concern - to say the least" about the proposed takeover.
The committee "wants a lot more information" about the effect of the deal on UK science and intellectual property, he said.The committee "wants a lot more information" about the effect of the deal on UK science and intellectual property, he said.
Mr Miller confirmed he would be urging his committee to call senior executives from both companies.Mr Miller confirmed he would be urging his committee to call senior executives from both companies.
Pressure is mounting from UK politicians over the proposed takeover. Business Secretary Vince Cable will also make a statement to MPs about the proposed takeover in the House of Commons at 15:30.
Labour leader Ed Miliband has called for an inquiry into the proposal. Earlier, the Prime Minister's spokesman said the deal had been discussed in Cabinet, and that both David Cameron and Mr Cable were in "complete agreement" over the government's approach to the Pfizer proposal.
Downing Street added the government was sticking to a policy of "active engagement" with both Pfizer and AstraZeneca, while not interfering with what was ultimately a decision for shareholders.
Inquiry
The PM's spokesman said it was "significant that Pfizer has sought engagement... to understand the government's views and the approach".
The spokesman added it was "entirely a matter for the companies, their boards and their shareholders". But the government still wanted "engagement" regarding scientific research and development.
At the weekend, Labour leader Ed Miliband called for an inquiry into the proposal.
"We need a proper, independent assessment of whether this [deal] is in our national interest," Mr Miliband told the BBC."We need a proper, independent assessment of whether this [deal] is in our national interest," Mr Miliband told the BBC.
No 10 denied Labour claims it is acting as a "cheerleader" for the deal, saying it is fighting for British jobs and British science. No 10 denied Labour allegations that it was acting as a "cheerleader" for the deal, saying it was fighting for British jobs and British science.
AstraZeneca has rejected two multi-billion dollar offers from Pfizer. Tax
Last week Pfizer made an offer which valued AstraZeneca at £63bn, a rise on its initial offer of almost £59bn. Sir David said "tax was one of the key drivers " behind the Pfizer offer for AstraZeneca, rather than a long-term commitment to research and development.
"That is a very narrow basis on which to base such a massive task," Sir David told the BBC.
"The risk is that the past history of Pfizer has shown that they tend to extract destructive synergies, they have done that in the past.
"I have a great concern that they will act like a praying mantis and suck the lifeblood out of their prey."
AstraZeneca's management team is holding a presentation for investors and analysts on Tuesday to promote its own achievements and to demonstrate the firm's "excellent growth prospects".AstraZeneca's management team is holding a presentation for investors and analysts on Tuesday to promote its own achievements and to demonstrate the firm's "excellent growth prospects".
In a shareholder update on Tuesday it forecast annual revenues of greater than $45bn (£26.6bn) by 2023. The company had revenues of $25.7bn in 2013. In a shareholder update on Tuesday, it forecast annual revenues of greater than $45bn (£26.6bn) by 2023. The company had revenues of $25.7bn in 2013.